GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pasithea Therapeutics
Pasithea Therapeutics is a mental health company. Its stock price reflects its efforts to develop both clinical trials and new drugs. The chart is a story of transformation and the search for an effective business model.
Share prices of companies in the market segment - Neuro
Pasithea Therapeutics is a life sciences company that operates a network of clinics providing ketamine infusion therapy for mental health disorders. We've categorized it under "Neurology." The chart below shows the dynamics of the innovative depression treatment sector.
Broad Market Index - GURU.Markets
Pasithea Therapeutics is a biotech company developing drugs to treat diseases of the central nervous system. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
KTTA - Daily change in the company's share price Pasithea Therapeutics
For Pasithea Therapeutics Corp., a mental health company, daily volatility reflects sensitivity to news about its clinics. This metric is an indicator of demand for innovative depression treatments.
Daily change in the price of a set of shares in a market segment - Neuro
Pasithea Therapeutics operates clinics providing mental health treatments, including ketamine therapy. This is a new and rapidly growing field of medicine. The chart below shows volatility in the healthcare sector, helping to assess KTTA's performance against broader trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Pasithea Therapeutics is a biotech company working on treatments for neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pasithea Therapeutics
For Pasithea Therapeutics Corp., year-over-year performance tells the story of its unique business model. Its 12-month market cap reflects both the performance of its network of ketamine-based mental health clinics and the progress of its own oncology drug development, making it a complex hybrid.
Annual dynamics of market capitalization of the market segment - Neuro
Pasithea, a company offering innovative treatments for mental disorders, is a bet on the future of psychiatry. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its approaches, such as ketamine-based therapy.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pasithea Therapeutics, a company that operates clinics offering intravenous ketamine therapy for mental disorders, is at the forefront of innovative psychiatry. Its year-over-year market capitalization growth demonstrates the growing recognition of ketamine as a fast-acting antidepressant.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pasithea Therapeutics
Pasithea Therapeutics is a mental health company. Its monthly performance depends on the success of its clinics and progress in developing new drugs. News about clinic network expansion and clinical trials are the main drivers.
Monthly dynamics of market capitalization of the market segment - Neuro
Pasithea Therapeutics operates clinics for the treatment of mental disorders using intravenous ketamine and develops new drugs for the central nervous system. It operates a hybrid model. The healthcare and biotech sector chart reflects the general trends that drive Pasithea's development of both its services and research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pasithea Therapeutics, a mental health company, is focused on innovative treatments. Its shares are driven by news of clinical trials and new center openings, rather than by general market trends, creating an independent profile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pasithea Therapeutics
Pasithea Therapeutics, a company that operates clinics providing intravenous ketamine therapy for mental health disorders, operates in an emerging market. Its weekly stock price reflects regulatory changes, public acceptance of this treatment method, and its ability to expand its clinic network.
Weekly dynamics of market capitalization of the market segment - Neuro
Pasithea Therapeutics operates a network of clinics using ketamine therapy and develops new drugs for the treatment of mental disorders. Its business is a hybrid of medical services and biotech. The chart below shows how investors view this model and how it relates to the healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pasithea Therapeutics operates ketamine therapy clinics. Its business is at the intersection of medicine and biotech. The chart will show how investors view this model and how it compares to the broader market, responding to regulatory and expansion news.
Market capitalization of the company, segment and market as a whole
KTTA - Market capitalization of the company Pasithea Therapeutics
Pasithea Therapeutics' market capitalization reflects investors' valuation of its new focus on drug development following the closure of its ketamine clinic chain. The chart shows how the market values its neuroscience research programs. Its low valuation reflects the high risk associated with early-stage biotech development.
KTTA - Share of the company's market capitalization Pasithea Therapeutics within the market segment - Neuro
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for mental health disorders. Its market share in the healthcare sector is small, but it operates in a rapidly growing segment. Its market capitalization reflects both its clinical business and its own pharmaceutical developments.
Market capitalization of the market segment - Neuro
This chart shows the total value of the entire neuroscience pharmaceutical sector. For Pasithea Therapeutics, which operates in this field, this line is a map of hope and risk. Its dynamics reflect the extent to which investors are willing to invest in one of the most complex and unpredictable areas of pharmaceuticals, where the company conducts its research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pasithea Therapeutics operates clinics offering treatment for mental disorders, including ketamine therapy. Its market capitalization is determined by its innovative approaches to psychiatry. Its market share is determined by its position at the intersection of medicine and wellness.
Book value capitalization of the company, segment and market as a whole
KTTA - Book value capitalization of the company Pasithea Therapeutics
Pasithea Therapeutics is a company providing mental health services, including ketamine therapy. Its book value is its tangible assets: its network of clinics, equipment, and financial capital. This is the tangible foundation for innovative treatments. How has it grown? The chart below shows.
KTTA - Share of the company's book capitalization Pasithea Therapeutics within the market segment - Neuro
Pasithea Therapeutics is a mental health company. Its business can range from drug development (requiring laboratories) to the management of clinics, which are its primary physical assets. The chart shows its share of the physical infrastructure serving the mental health sector.
Market segment balance sheet capitalization - Neuro
Pasithea Therapeutics is a mental health company. In a capital-intensive sector, its model is hybrid. The industry's asset chart reflects the value of clinics. Pasithea owns them, but also develops asset-light drugs.
Book value of all companies included in the broad market index - GURU.Markets
Pasithea Therapeutics' assets include a network of clinics in the UK and US offering innovative treatments for mental disorders, such as intravenous ketamine therapy, as well as developing proprietary drugs. Its book value reflects the physical scale of its clinics and R&D capabilities.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pasithea Therapeutics
Pasithea Therapeutics is a mental health company. Its market capitalization reflects its clinical management business and its pharmaceutical development. This reflects its integrated approach to treating mental disorders.
Market to book capitalization ratio in a market segment - Neuro
Pasithea Therapeutics is a mental health company. Its valuation on this chart reflects both the growth potential of this important sector and the risks associated with developing new treatments and commercializing them.
Market to book capitalization ratio for the market as a whole
Pasithea Therapeutics operates clinics and develops medications in the mental health field. It operates a hybrid model that combines medical services and biotech research. This metric helps understand how the market values this combination of a stable service business and risky R&D.
Debts of the company, segment and market as a whole
KTTA - Company debts Pasithea Therapeutics
Pasithea, a company that operates a network of clinics for the treatment of mental disorders, including innovative methods, is using capital to expand its network. This chart shows the investment required to scale its service-based medical model in the growing mental health sector.
Market segment debts - Neuro
Pasithea Therapeutics operates a network of clinics providing ketamine infusion therapy for mental health disorders and also develops new drugs. This chart shows how the company, with its hybrid model (services and R&D), manages its capital, balancing clinical operations with risky biopharmaceutical investments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pasithea Therapeutics
Pasithea Therapeutics operates in the mental health field, including operating ketamine therapy clinics. Opening and equipping medical centers, as well as conducting scientific research, require investment. This chart shows how the company uses debt capital to expand its clinic network and fund R&D.
Market segment debt to market segment book capitalization - Neuro
Pasithea Therapeutics is a mental health company. It operates clinics offering innovative treatments, such as ketamine therapy. This chart shows how the company is funding the expansion of its clinic network, comparing its debt to the market capitalization of the entire healthcare sector.
Debt to book value of all companies in the market
Pasithea Therapeutics operates a network of clinics offering ketamine infusions for the treatment of mental disorders. Expanding the network of medical facilities requires investments in rent, equipment, and personnel. How is the company financing its expansion? This graph of total debt in the economy helps assess the sustainability of its financial model.
P/E of the company, segment and market as a whole
P/E - Pasithea Therapeutics
Pasithea Therapeutics is a company focused on both developing new drugs for the treatment of mental disorders and operating clinics providing ketamine therapy. This chart shows how investors view this hybrid business model.
P/E of the market segment - Neuro
Pasithea Therapeutics is a biotech company that also operates a network of clinics providing intravenous ketamine therapy for the treatment of mental disorders. This chart illustrates the average valuation in the neuroscience sector, combining the risks of biotech development with those of operating in the healthcare sector.
P/E of the market as a whole
Pasithea Therapeutics is a biotech company that may be developing new treatments for psychiatric and neurological disorders. This chart reflects investors' overall risk appetite. It helps understand whether KTTA's valuation reflects speculative interest in its research or whether it follows broader trends in the biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pasithea Therapeutics
Pasithea Therapeutics is a mental health company. It operates clinics offering ketamine therapy and develops new drugs for the treatment of mental disorders. This chart reflects investor expectations for the future growth of the mental health market and the success of its pharmaceutical developments.
%20P%2FE%20Pasithea%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pasithea-Therapeutics&v=1772665081565 "Chart of the company's future (projected) P/E Pasithea Therapeutics")
Future (projected) P/E of the market segment - Neuro
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for mental disorders and is also developing new drugs. The chart reflects future revenue projections for the sector, helping to understand how the market views its dual model—clinics and R&D—in the new era of psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772665081571 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for mental health disorders and also has its own research and development efforts. This market sentiment chart reflects investor sentiment toward innovative approaches in mental health and their willingness to invest in new treatments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772665081595 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pasithea Therapeutics
Pasithea Therapeutics is a biotech company that previously operated mental health clinics and now focuses on developing new drugs for the central nervous system. This chart reflects the financial results of its business transformation from a service provider to an R&D company.
Profit of companies in the market segment - Neuro
Pasithea Therapeutics operates a network of clinics providing ketamine infusions for the treatment of psychiatric disorders and is also developing new drugs for the central nervous system. This is a hybrid business model. This chart shows the overall profitability of the neuroscience sector, where the combination of services and pharmaceutical development can create synergies and diversify revenue.
Overall market profit
Pasithea Therapeutics is a mental health company. The need for mental health treatments is independent of economic conditions and can even increase during periods of uncertainty. The company's success is determined by the effectiveness of its treatments, not by the macroeconomic trends reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pasithea Therapeutics
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for mental disorders and is also developing pharmaceuticals. Future profits depend on the growth of its clinical business. This chart reflects analyst expectations for expanding access to alternative treatments for depression.
%20profit%20of%20the%20company%20Pasithea%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pasithea-Therapeutics&v=1772665081658 "Graph of future (projected) profit of the company Pasithea Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Pasithea Therapeutics operates a network of clinics offering ketamine infusion therapy for psychiatric disorders and is also developing new drugs for the central nervous system. This dual strategy combines current revenue with long-term potential. This chart shows revenue projections for the neuroscience sector, helping to evaluate Pasithea's hybrid model.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772665081668 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Pasithea Therapeutics is a mental health company, operating clinics and developing medications. Demand for its services is growing, but depends on insurance coverage. This economic outlook impacts the overall solvency of the healthcare system and people's willingness to spend on mental health.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772665081697 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pasithea Therapeutics
Pasithea Therapeutics operates in the mental health sector, operating clinics and developing new drugs. Its revenue is dual-produced. This chart shows how investors view its hybrid model: stable revenue from clinics and high-risk, but risky, potential from pharmaceutical development.
P/S market segment - Neuro
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for psychiatric disorders resistant to traditional treatments. The company is also developing new CNS drugs. This chart reflects the average revenue estimate for the sector, helping to assess how the market views this dual business model in mental health.
P/S of the market as a whole
Pasithea Therapeutics operates a network of clinics offering ketamine infusion therapy for mental disorders and also conducts its own research. This chart helps understand how the market is evaluating a hybrid model combining medical services and biotech research in the emerging field of psychiatry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pasithea Therapeutics
Pasithea Therapeutics is a biotech company that also operates a network of clinics providing ketamine infusion therapy for mental health disorders. Its future revenue estimates reflect the prospects for both businesses. The chart shows how investors view the growth in demand for innovative depression treatments and the success of its pharmaceutical developments.
%20P%2FS%20Pasithea%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pasithea-Therapeutics&v=1772665081811 "The graph of the company's future (projected) P/S Pasithea Therapeutics")
Future (projected) P/S of the market segment - Neuro
Pasithea Therapeutics is a biotech company that previously operated ketamine clinics and is now focused on developing drugs for the treatment of central nervous system disorders. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its new research focus and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772665081833 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Pasithea Therapeutics operates a network of clinics providing intravenous ketamine therapy for mental disorders and is also developing new drugs. This hybrid model combines current revenue with venture capital exposure. This graph of investor expectations reflects their interest in new approaches to treating mental illness.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772665081848 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pasithea Therapeutics
The chart illustrates the financial performance of Pasithea Therapeutics, a company that previously operated ketamine therapy clinics and is now focused on developing CNS drugs. Revenue may be volatile, reflecting the company's transition and shift in focus to biotech research.
Sales of companies in the market segment - Neuro
Pasithea Therapeutics is a biotech company that also operates a network of clinics offering intravenous ketamine therapy for mental health disorders. Its revenue structure is unique, combining revenue from medical services with potential future revenue from drug development.
Overall market sales
Pasithea Therapeutics operates clinics providing ketamine-based therapy for mental disorders and also conducts its own research. The company operates in the innovative field of psychiatry. This overall economic outlook does not impact the growing need for new and effective treatments for depression and other conditions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pasithea Therapeutics
Pasithea Therapeutics is a biotech company focused on neuroscience and operates a network of clinics offering mental health treatments, including ketamine infusions. Revenue growth depends on both the success of development and the expansion of its clinical business. The chart reflects analyst expectations for both areas of business.
%20sales%20of%20the%20company%20Pasithea%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pasithea-Therapeutics&v=1772665081898 "Schedule of future (projected) sales of the company Pasithea Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Pasithea Therapeutics operates clinics providing ketamine therapy for mental health disorders. This chart shows the outlook for the healthcare sector. Is demand for innovative depression treatments growing, creating a new market niche? This reflects general trends in psychiatry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772665081911 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Pasithea Therapeutics is a biotech company focused on neuroscience and also operates clinics offering treatment for mental health disorders. Clinical business depends on demand for services and insurance coverage, while biotech developments depend on science. This dynamic can influence people's willingness to pay for treatment, but demand is often inelastic.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772665081919 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pasithea Therapeutics
Pasithea Therapeutics is a mental health company that provides both clinical treatment services (such as ketamine therapy) and develops new medications. This chart shows the financial performance of its hybrid model. Profitability depends on patient volume in its clinics and the long-term success of its pharmaceutical development pipeline.
Market segment marginality - Neuro
Pasithea Therapeutics Corp. is a biotech company that initially focused on mental health treatment clinics before shifting its focus to drug development. This chart reflects its financial position during this transformation, with profitability dependent on the success of its new R&D strategy.
Market marginality as a whole
Pasithea Therapeutics, operating in neuroscience, likely focuses on innovative treatments for mental disorders. The company's success depends on clinical trial results. This gross margin chart reflects investors' willingness to fund long-term, risky biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Pasithea Therapeutics
Pasithea Therapeutics is a mental health company. It initially operated ketamine clinics but later shifted its focus to drug development. This chart may reflect this transformation: it is cutting clinic-related staff and hiring scientists for a new neuroscience R&D unit.
Share of the company's employees Pasithea Therapeutics within the market segment - Neuro
Pasithea Therapeutics not only develops medications for mental health disorders but also operates a network of clinics. This hybrid model requires both scientists for R&D and physicians and clinical staff. This chart shows the company's combined labor market share, reflecting its unique approach integrating pharmaceuticals and healthcare delivery.
Number of employees in the market segment - Neuro
Pasithea Therapeutics operates a network of clinics providing intravenous ketamine therapy for mental disorders and is also developing new drugs. The chart shows its employment in the neuroscience sector. The company combines clinical services with biotech research, a hybrid business model.
Number of employees in the market as a whole
Pasithea Therapeutics operates clinics offering ketamine-based therapy and develops new medications for the treatment of mental disorders. This is a new and rapidly growing field. The company's growth is driven by both demand for its services and scientific developments. It represents a new healthcare sector, creating its own job market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pasithea Therapeutics (KTTA)
Pasithea Therapeutics is a biotech company that, after restructuring, focused on R&D in neuroscience (e.g., multiple sclerosis). This chart shows the speculative value of their R&D. It reflects the market capitalization per scientist, which is a bet on the success of their early research projects.
%20of%20the%20company%20Pasithea%20Therapeutics%20(KTTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pasithea-Therapeutics-KTTA&v=1772665082036 "Chart of market capitalization per employee (in thousands of dollars) of the company Pasithea Therapeutics (KTTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Pasithea Therapeutics (KTTA) operates a network of clinics providing intravenous ketamine treatment for mental health disorders. In this innovative healthcare field, this metric reflects both the effectiveness of the business model and confidence in the new treatment method. A high per-employee ratio may indicate high profitability and potential for scalability of the clinic network.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772665082056 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Pasithea Therapeutics is a mental health company. Its business model encompasses both clinical management and drug development. This metric reflects the company's hybrid nature. The market evaluates both the operational efficiency of its clinics and the long-term potential of its neuroscience research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772665082126 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pasithea Therapeutics (KTTA)
Pasithea Therapeutics is a mental health company. Previously operating ketamine clinics, it now focuses on the R&D of new drugs. This chart shows the loss per employee, which is typical for the R&D phase. It reflects the investment in scientists working on new treatments for mental disorders.
%20Chart%20Pasithea%20Therapeutics%20(KTTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pasithea-Therapeutics-KTTA&v=1772665082241 "Company Profit Per Employee (in thousands of dollars) Chart Pasithea Therapeutics (KTTA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Pasithea Therapeutics Corp. is a biotech company focused on neuroscience and owns a network of clinics offering intravenous ketamine therapy. For this hybrid model, efficiency per employee reflects the synergy between R&D and clinical practice. The graph shows the overall profitability of a company combining science and service.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772665082321 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Pasithea Therapeutics, a company that initially operated ketamine therapy clinics, has now shifted its focus to biotech R&D. It's a complex transformation. This chart, showing average market profitability, helps us understand how the R&D model differs from the service-based medical business (clinics).
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772665082422 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pasithea Therapeutics (KTTA)
Pasithea Therapeutics operates in the mental health field, including the use of innovative treatments. While this figure may be modest during the business's development phase, growth will reflect the expansion of its clinic network, increased patient volume, and recognition of its depression treatment approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pasithea-Therapeutics-KTTA&v=1772665082468 "Sales chart per company employee Pasithea Therapeutics (KTTA)")
Sales per employee in the market segment - Neuro
Pasithea Therapeutics (KTTA) is a biotech focused on treating mental disorders. They develop new drugs (R&D) and previously operated ketamine treatment clinics. This chart shows the average output in the sector. For KTTA, this is an indicator of how productive (cost-effective) their R&D team is in creating new drugs.
Sales per employee for the market as a whole
Pasithea Therapeutics operates a network of clinics offering intravenous ketamine therapy for mental health disorders. It's a medical services business, and by its very nature, it's labor-intensive. This indicator shows how efficiently their clinics and medical staff generate revenue from treatments.
Short shares by company, segment and market as a whole
Shares shorted by company Pasithea Therapeutics (KTTA)
Pasithea (KTTA) is a biotech company that also operated ketamine clinics for depression. This chart shows the volume of bearish bets. The shorts may be due to doubts about the effectiveness of this therapy or the sustainability of the business model, which combines R&D and clinic management.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pasithea-Therapeutics-KTTA&v=1772665082668 "Short Shares Chart for the Company Pasithea Therapeutics (KTTA)")
Shares shorted by market segment - Neuro
Pasithea Therapeutics (KTTA) is a biotech company that operates clinics providing ketamine infusions for the treatment of mental disorders and is also developing new drugs. This chart aggregates short positions in the neuroscience biotech sector. It reflects investor skepticism about the business model of ketamine clinics.
Shares shorted by the overall market
Pasithea Therapeutics, a biotech company previously working with psychedelics, is now focused on neuroscience. This chart illustrates the overall market pessimism. A change in R&D focus is a "red flag." When investors are fearful, they see it as a sign of failure and are unwilling to fund a "second attempt" by selling off shares.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pasithea Therapeutics (KTTA)
Pasithea Therapeutics is a biotech company working in the complex field of neurology (depression, ALS). This is risky R&D. This graph is a "cardiogram" of speculation. It can remain "cold" for a long time during research, then suddenly "overheat" on any positive news about drug development.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pasithea-Therapeutics-KTTA&v=1772665082710 "RSI 14 indicator chart for the company's stock Pasithea Therapeutics (KTTA)")
RSI 14 Market Segment - Neuro
Pasithea (KTTA) is a biotech company focused on neuroscience. Historically, they operated clinical trials (ketamine), but are now focusing on developing new CNS drugs. This chart measures the pulse of the Neuroscience sector. It helps differentiate KTTA's performance from general "overheating" or "overselling" in the entire biotech sector.
RSI 14 for the overall market
For Pasithea (KTTA), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KTTA (Pasithea Therapeutics)
Pasithea Therapeutics is a biotech company focused on developing new treatments for central nervous system disorders (depression, multiple sclerosis). This chart shows the speculative average price target from analysts, which is almost entirely based on their assessment of the scientific potential of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KTTA-Pasithea-Therapeutics&v=1772665082809 "A chart showing analyst consensus forecasts for the expected stock price. KTTA (Pasithea Therapeutics)")
The difference between the consensus estimate and the actual stock price KTTA (Pasithea Therapeutics)
Pasithea (KTTA) is a clinical-stage biotech focused on developing novel treatments for neurological diseases. This chart clearly demonstrates the "gap" between the market price and where analysts expect it to go. For an R&D company, this gap reflects their faith (or skepticism) in scientific breakthroughs and clinical trial success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KTTA-Pasithea-Therapeutics&v=1772665082847 "A chart showing the difference between the consensus forecast and the actual stock price. KTTA (Pasithea Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Pasithea is a biotech R&D company that, after several pivots, has shifted its focus to developing new drugs for neurological diseases. This chart reflects analysts' overall expectations for the neuroscience sector, demonstrating whether experts believe junior biotechs will succeed.
Analysts' consensus forecast for the overall market share price
Pasithea Therapeutics is a biotech company operating in the mental health and neuroscience sector. This is a high-risk sector, where stock prices are based on future expectations. This chart reflects the overall risk appetite in the market. When analysts are optimistic (the chart rises), investors are more willing to invest in speculative biotechs, providing them with the funding they need for development.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pasithea Therapeutics
Pasithea is a mental health clinic. They started as an R&D company and now operate a network of clinics (in the US and UK) that provide ketamine infusions (and other innovative treatments) for treatment-resistant depression. This chart is a summary of their service model. It reflects their ability to scale their clinic network and their reliance on demand for these alternative treatments.
AKIMA Market Segment Index - Neuro
Pasithea Therapeutics operates clinics specializing in mental health and neurological disorders. While many in the neuro sector focus on drug development, Pasithea focuses on providing treatments. This chart compares their comprehensive index to the industry average, showing how their business model compares to their competitors.
The AKIM Index for the overall market
Pasithea Therapeutics is a biotech company developing vaccines for psychiatric and neurological disorders (including MS). This chart, which reflects the market average, provides a macro backdrop. It helps assess how KTTA, an early-stage scientific story, compares to overall economic trends.
